Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma.

Nat Commun · 2021 · PMC8408158 · PMID 34465776

Europe PMC DOI

hedged sentence

0.0620

closest p · 1.2× alpha

0.0620

boldest claim

The sentences

showed a trendp = 0.062so close (0.05 < p ≤ 0.1)

Patients harboring NRAS mutations also showed a trend towards unfavorable LSS ( p = 0.062, q = 0.187, log rank test; Fig. 3e ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.